Analyst Price Target is $7.50
▲ +455.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adicet Bio in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 455.56% upside from the last price of $1.35.
Current Consensus is
Moderate Buy
The current consensus among 4 polled investment analysts is to moderate buy stock in Adicet Bio. This Moderate Buy consensus rating has held steady for over two years.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More
